Science doesn't happen in a vacuum; it is driven by policy and funding. For decades, rare neurodegenerative diseases were ignored by big pharma because the "market" was too small. That changed with the passing of key legislation that provided tax breaks and extended patent protection for orphan drugs. In 2026, we are seeing the next wave of policy shifts, focusing on "Right to Try" laws and...
0 Commentarios
0 Acciones
231 Views
0 Vista previa
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek